Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.44 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL724015 | 0.90 | CNR2 (0.55) | MAPTKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL724190 | 0.88 | ALDH1A1 (0.54) | MAPTKDM4EHPGDMEN1KMT2A | |
| SCHEMBL725347 | 0.85 | TUBB4A (0.56) | TUBB1PDE2A | |
| SCHEMBL724076 | 0.82 | CYP1A2 (0.51) | MAPTKDM4EHPGDMEN1KMT2A | |
| SCHEMBL786633 | 0.81 | ALDH1A1 (0.46) | MAPTKDM4EHPGDMEN1KMT2A | |
| SCHEMBL786846 | 0.80 | HSD17B14 (0.44) | MAPTKDM4EHPGDMEN1KMT2A | |
| SCHEMBL723931 | 0.79 | TUBB1 (0.57) | TUBB1 | |
| SCHEMBL25479020 | 0.78 | TUBB4A (0.47) | TUBB1PDE2A | |
| SCHEMBL15909613 | 0.78 | TUBB4A (0.42) | TUBB1PDE2A | |
| SCHEMBL724208 | 0.78 | ALDH1A1 (0.48) | MAPTKDM4EHPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-06-12 | — | — | US | disclosed |
| CN-119548495-A | Use of (substituted 1H-imidazol-4-yl) (3, 4, 5-trimethoxyphenyl) methanones for the treatment of coronaviruses | 维鲁公司 | 2025-03-04 | — | — | CN | disclosed |
| EP-4504183-A1 | METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS | Veru Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| US-12187720-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-01-07 | — | — | US | disclosed |
| CN-118984703-A | Methods of treating influenza and poxvirus infections | 维鲁公司 | 2024-11-19 | — | — | CN | disclosed |
| US-20240180879-A1 | METHODS OF TREATING INFLAMMATION | VERU INC. (US) | 2024-06-06 | — | — | US | disclosed |
| EP-4320151-A1 | METHODS OF TREATING INFLAMMATION | Veru Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| CN-117396505-A | Methods of treating inflammation | 维鲁公司 | 2024-01-12 | — | — | CN | disclosed |
| WO-2023196632-A1 | METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS | VERU INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230321045-A1 | METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS | VERU INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20130197049-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-08-01 | — | — | US | disclosed |
| EP-2608671-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Gtx, Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| EP-2542081-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Gtx, Inc. (US) | 2013-01-09 | — | — | EP | disclosed |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2012-03-22 | — | — | US | disclosed |
| WO-2012027481-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2011-10-20 | — | — | US | disclosed |
| WO-2011109059-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
| EP-2303021-A2 | COMPOUNDS FOR THE TREATMENT OF CANCER | University of Tennessee Research Foundation (US) | 2011-04-06 | — | — | EP | disclosed |
| WO-2010074776-A2 | COMPOUNDS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20090326020-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187720-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | MAPT 2614/4885KDM4E 1179/4885HPGD 522/4885 |
| US-20090326020-A1 | COMPOUNDS FOR TREATMENT OF CANCER | HCCS, NQO1, CCNY | MAPT 4836/4885KDM4E 1473/4885HPGD 116/4885 |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | MAPT 2614/4885KDM4E 1179/4885HPGD 522/4885 |
| US-20240180879-A1 | METHODS OF TREATING INFLAMMATION | IL1B, PYCARD, TUBB1 | MAPT 36/4885KDM4E 3914/4885HPGD 3125/4885 |
| US-20130197049-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | MAPT 2614/4885KDM4E 1179/4885HPGD 522/4885 |
| US-20230321045-A1 | METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS | TUBB3, TUBB1, TUBB | MAPT 45/4885KDM4E 3645/4885HPGD 3032/4885 |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | MAPT 2614/4885KDM4E 1179/4885HPGD 522/4885 |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | MAPT 2614/4885KDM4E 1179/4885HPGD 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.